{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:17:47Z","timestamp":1777918667663,"version":"3.51.4"},"reference-count":40,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100008615","name":"lineberger comprehensive cancer center, university of north carolina at chapel hill","doi-asserted-by":"publisher","award":["550KR221903"],"award-info":[{"award-number":["550KR221903"]}],"id":[{"id":"10.13039\/100008615","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Tumori"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Most patients with cancer do not participate in a clinical trial. Understanding clinical participation rates, and the barriers and motivators that influence participation may help identify opportunities for improvement in accrual.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A cross-sectional analysis of cancer survivors was conducted using the Health Information National Trends Survey (HINTS) administered in 2020. Primary outcome was clinical trial participation amongst patients with cancer. Secondary outcomes were motivators and barriers to influence clinical trial participation. Logistic regression was employed to assess the association of clinical trials being discussed as a cancer treatment option with social determinants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Six hundred and eighteen respondents (weighted population estimate 22,723,047) with a self-reported history of cancer were included. Overall, 15.7% reported an invitation to participate in a clinical trial, of which 37.8% participated. Clinical trials were discussed as a cancer treatment option amongst 13.5% of respondents. Knowledge of clinical trials was low (9.3%). Reported motivators included trying new care (72.3%), wanting to get better (88.9%), getting paid (40.1%), helping other people (73.0%), and encouragement from the doctor (73.7%) or family\/friends (59.5%). Reported barriers included getting transportation, childcare or paid time off work (42.4%), and standard care not covered by insurance (69.6%). Race (Other, OR 3.84) and income (&lt;$35k, OR 5.84) were associated with discussion of clinical trials as a cancer treatment option.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Clinical trial treatment discussion, invitation, and participation are low among patients with a history of cancer. Although the study identified multiple motivators and barriers to participation, improvement in the rates of discussion and invitation to participate in a clinical trial are required. Nevertheless, addressing the identified barriers and motivators that influence clinical trial participation may be a strategy to optimize patient enrollment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03008916251347175","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T06:47:06Z","timestamp":1749710826000},"page":"349-359","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Engagement in cancer clinical trials among a nationally representative cancer survivor sample: Motivators, barriers and opportunities for improvement"],"prefix":"10.1177","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5631-3709","authenticated-orcid":false,"given":"Zachary S.","family":"Feuer","sequence":"first","affiliation":[{"name":"Department of Urology, University of North Carolina at Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard S.","family":"Matulewicz","sequence":"additional","affiliation":[{"name":"Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramsankar","family":"Basak","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna A.","family":"Culton","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of North Carolina at Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Weaver","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology &amp; Hepatology, University of North Carolina at Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristalyn","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, University of North Carolina at Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Jui","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Urology, University of North Carolina at Chapel Hill, NC, USA"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy L.","family":"Rose","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC, USA"},{"name":"Division of Oncology, University of North Carolina at Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Milowsky","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC, USA"},{"name":"Division of Oncology, University of North Carolina at Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc A.","family":"Bjurlin","sequence":"additional","affiliation":[{"name":"Department of Urology, University of North Carolina at Chapel Hill, NC, USA"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"National Cancer Institute. What Are Cancer Clinical Trials? https:\/\/www.cancer.gov\/about-cancer\/treatment\/clinical-trials\/what-are-trials (2016 accessed 8 November 2022)."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(99)00141-9"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2018.08.001"},{"key":"e_1_3_2_5_2","volume-title":"Cancer Clinical Trials: Opportunities for Increasing Enrollment","author":"Harris Interactive","year":"2000","unstructured":"Harris Interactive. Cancer Clinical Trials: Opportunities for Increasing Enrollment (Study No. 11799). New York, NY: Harris Interactive, 2000."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.105"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy221"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34455"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5953"},{"key":"e_1_3_2_10_2","first-page":"113","article-title":"Perceptions of clinical trial participation in African American cancer survivors and caregivers","volume":"49","author":"Granda-Cameron C","year":"2022","unstructured":"Granda-Cameron C, McLean Florence Y, Whitfield-Harris L, et al. Perceptions of clinical trial participation in African American cancer survivors and caregivers. Oncol Nurs Forum 2022; 49: 113-124.","journal-title":"Oncol Nurs Forum"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21638"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.37573"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.22.2720"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00001"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2022.07.006"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13187-020-01790-6"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.4553"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5020"},{"key":"e_1_3_2_19_2","unstructured":"National Cancer Institute. Health Information National Trends Survey https:\/\/hints.cancer.gov\/ (accessed 14 July 2021)."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.12.812"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa155"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.1235"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-13-19"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2010.12.003"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2015.05.020"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.2969"},{"key":"e_1_3_2_27_2","first-page":"559","article-title":"Selection factors in clinical trials: results from the Community Clinical Oncology Program Physician\u2019s Patient Log","volume":"71","author":"Hunter CP","year":"1987","unstructured":"Hunter CP, Frelick RW, Feldman AR, et al. Selection factors in clinical trials: results from the Community Clinical Oncology Program Physician\u2019s Patient Log. Cancer Treat Rep 1987; 71: 559\u2013565.","journal-title":"Cancer Treat Rep"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_243729"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_156686"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30689"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMhpr1707176"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.7305"},{"key":"e_1_3_2_33_2","unstructured":"Luj\u00e1n B. R. H.R. 913 \u2013 CLINICAL TREATMENT Act 116th Congress (2019\u20132020). Congress.gov. https:\/\/www.congress.gov\/bill\/116th-congress\/house-bill\/913 (accessed 26 August 2021)."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_100021"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1080\/10810730.2010.525296"},{"key":"e_1_3_2_36_2","unstructured":"ACCC. ACCC Community Oncology Research Institute https:\/\/www.accc-cancer.org\/home\/learn\/research-clinical-trials\/accc-community-oncology-research-institute (accessed 8 September 2021)."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.2137"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00369-7"},{"key":"e_1_3_2_39_2","unstructured":"Coalition for Clinical Trials Awareness. Coalition for Clinical Trials Awareness Home http:\/\/cctawareness.org\/ (accessed 8 November 2022)."},{"key":"e_1_3_2_40_2","unstructured":"Center for Information & Study on Clinical Research Participation. Home https:\/\/www.ciscrp.org\/ (accessed 8 November 2022)."},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3868"}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03008916251347175","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03008916251347175","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03008916251347175","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:43:47Z","timestamp":1777661027000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03008916251347175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1177\/03008916251347175"],"URL":"https:\/\/doi.org\/10.1177\/03008916251347175","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]}}}